



NDA 21-595/S002

Indevus Pharmaceuticals, Inc.
Attention: John Berryman
Vice President, Regulatory Affairs & Pharmaceutical Sciences
99 Hayden Avenue, Suite 200
Lexington, MA 02421-7966

Dear Mr. Berryman:

Please refer to your supplemental new drug application dated January 23, 2006, received January 24, 2006, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Santura™ (trospium chloride), 20 mg twice daily, for the treatment of overactive bladder.

This Prior Approval supplemental new drug application contained a final study report for a drug-drug interaction study entitled "The Effect of Multiple Doses of Trospium Chloride on the Single Dose Pharmacokinetics of Digoxin: A Single Center, Open-Label, Partially Randomized Two Period, Crossover, Drug-Drug Interaction Study" and proposed labeling changes to the package insert (PI) based on the results of this study.

We also acknowledge receipt of your submission, dated July 19, 2006, in response to our Approvable Letter issued for this supplement on July 12, 2006.

We completed our review of this application, as amended. This application is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert).

Please submit an electronic version of the FPL according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA*. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission "**FPL for approved supplement NDA 21-595/S-002.**" Approval of this submission by FDA is not required before the labeling is used.

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

NDA 21-595/S002

Page 2

If you have any questions, call Jean Makie, M.S., R.D., Sr. Regulatory Project Manager, at 301-796-0952.

Sincerely,

{See appended electronic signature page}

Mark Hirsch, M.D.
Acting Deputy Director
Division of Reproductive and Urologic Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

Enclosure

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Mark S. Hirsch
9/5/2006 03:09:25 PM